New Cross-Market ETFs Added as Fund Companies' Hong Kong Subsidiaries Compete to Launch New Products

Today, E Fund (Hong Kong) Solactive Biopharmaceuticals Select Index ETF officially listed on the Hong Kong Stock Exchange. This is the world’s first and currently the only biopharmaceutical-themed ETF that covers both the Hong Kong and U.S. stock markets, further enriching the cross-market ETF product matrix between Hong Kong and the U.S.

Notably, since this month, leading fund companies such as Harvest and China Asset Management have been active in Hong Kong subsidiaries. On March 6, Harvest China-US Technology 50 ETF was launched, and on March 18, China Asset Management Hong Kong-US Artificial Intelligence ETF was listed, both targeting core hot sectors like AI and technology. The trend of major institutions actively deploying cross-market ETFs is becoming increasingly evident.

Another New Cross-Market ETF Launch

On March 23, E Fund (Hong Kong) Solactive Biopharmaceuticals Select Index ETF (Code: 3186) was officially listed on the Hong Kong Stock Exchange. This is the world’s first and currently the only biopharmaceutical-themed ETF that covers both the Hong Kong and U.S. stock markets.

According to reports, this ETF tracks the Solactive Biopharmaceuticals Select Index, which selects 100 constituents from biopharmaceutical companies listed in Hong Kong and the U.S. As of March 5, 2026, 65% of the index components are from Hong Kong stocks, and 35% from U.S. stocks. It includes top global pharmaceutical leaders and cutting-edge technology companies in the U.S. market, while also deeply focusing on the growth dividends of China, the world’s second-largest pharmaceutical market.

It is worth noting that, unlike traditional market-cap weighted indices, the Solactive Biopharmaceuticals Select Index uses an equal-weighting approach, resulting in highly diversified individual stocks. Industry insiders point out: “The characteristics of the biopharmaceutical industry—where breakthrough innovations often come from small and medium-sized companies—a blockbuster drug approval can lead to exponential growth in market value. The equal-weight strategy helps increase the portfolio’s exposure to ‘disruptive innovation’ while effectively diversifying the tail risk concentrated in a few leading companies.”

According to data from Solactive and Bloomberg, as of February 9, 2026, the Solactive Biopharmaceuticals Index has increased by 140.31% since its base date on March 20, 2020. Additionally, over the past year, the index achieved a total return of 75.7%, significantly outperforming the Hang Seng Biotech Index and the S&P Biotechnology Index during the same period.

E Fund Asset Management (Hong Kong) Limited stated that biopharmaceuticals are a high-growth sector characterized by both rigid consumer demand and innovative growth potential. The global aging trend provides a long-term demand foundation for the industry, spanning 10 to 20 years.

Multiple Fund Companies’ Hong Kong Subsidiaries Continue to “Expand”

In addition to this product, the reporter observed that since this month, many fund companies’ Hong Kong subsidiaries have launched ETF products on the Hong Kong Stock Exchange, mainly targeting hot sectors like AI and biopharmaceuticals.

For example, the Harvest China-US Technology 50 ETF, launched on March 6, tracks the Solactive Harvest Tiger G2 Tech 50 Select Index. This index includes 30 leading Chinese technology companies listed in Hong Kong and 20 global tech giants listed in the U.S.

In terms of regional weightings, the index maintains approximately 62% Hong Kong stocks and 38% U.S. stocks. To balance growth potential and risk diversification, the index sets clear weight limits for individual constituents during rebalancing (8% for Hong Kong stocks and 5% for U.S. stocks).

Historical data shows that, as of December 31, 2025, the index’s cumulative return over the past three years reached 127.66%, with an annualized return of about 30.72%.

Similarly, the China Asset Management Hong Kong Artificial Intelligence ETF, launched on March 18, tracks the Solactive Hong Kong-U.S. Artificial Intelligence 50 Select Index, which includes up to 50 leading AI companies listed in Hong Kong and the U.S.

The index also employs regional weightings, with 62% in Hong Kong stocks and 38% in U.S. stocks, and sets strict limits on individual stock weights—8% for Hong Kong-listed companies and 5% for U.S.-listed companies.

Further analysis of these companies’ ETF portfolios reveals that E Fund (Hong Kong)’s ETF products mainly focus on industry sectors. Besides the Solactive Biopharmaceuticals Select Index ETF, they also include the CSI Liquor Index ETF, FTSE Artificial Intelligence Select Index ETF, and Solactive Global Gold Mining Index ETF, among others.

China Asset Management (Hong Kong) and Harvest International have also launched some traditional products, as well as innovative ones, such as virtual asset ETFs, including the China Asset Management Bitcoin ETF and Harvest Ethereum Spot ETF.